Advertisement

Cancer and Metastasis Reviews

, 25:409 | Cite as

TNF-α in promotion and progression of cancer

  • Frances Balkwill
Article

Abstract

Tumour necrosis factor alpha is a member of the TNF/TNFR cytokine superfamily. In common with other family members, TNF-α is involved in maintenance and homeostasis of the immune system, inflammation and host defence. However, there is a ‘dark side’ to this powerful cytokine; it is now clear that, especially in middle and old age, TNF-α is involved in pathological processes such as chronic inflammation, autoimmunity and, in apparent contradiction to its name, malignant disease. This article will discuss the involvement of TNF-α in the inflammatory network that contributes to all stages of the malignant process, and consider the possibility that TNF-α may be a target for cancer therapy.

Keywords

TNF-α Inflammation Cytokine Chemokine 

References

  1. 1.
    Akira, S., & Takeda, K. (2004). Toll-like receptor signalling. Nature Reviews. Immunology, 4, 499–511.CrossRefPubMedGoogle Scholar
  2. 2.
    Arnott, C. H., Scott, K. A., Moore, R. J., Hewer, A., Phillips, D. H., Parker P., et al. (2002). Tumour necrosis factor-α mediates tumour promotion via a PKCα-AP-1-dependent pathway. Oncogene, 21, 4728–4738.CrossRefPubMedGoogle Scholar
  3. 3.
    Arnott, C. H., Scott, K. A., Moore, R. J., Robinson, S. C., Thompson, R. G., & Balkwill, F. R. (2004). Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene, 23, 1902–1910.CrossRefPubMedGoogle Scholar
  4. 4.
    Balkwill, F. (2002). Tumor necrosis factor or tumor promoting factor? Cytokine & Growth Factor Reviews, 13, 135–141.CrossRefGoogle Scholar
  5. 5.
    Balkwill, F. (2004). The significance of cancer cell expression of CXCR4. Seminars in Cancer Biology, 14, 171–179.CrossRefPubMedGoogle Scholar
  6. 6.
    Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: Back to Virchow. Lancet, 357, 539–545.CrossRefPubMedGoogle Scholar
  7. 7.
    Balkwill, F., Charles, K. A., & Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7, 211–217.CrossRefPubMedGoogle Scholar
  8. 8.
    Bates, R. C., & Mercurio, A. M. (2003). Tumor necrosis factor-α stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Molecular Biology of the Cell, 14, 1790–1800.CrossRefPubMedGoogle Scholar
  9. 9.
    Bozcuk, H., Uslu, G., Samur, M., Yildiz, M., Ozben, T., Ozdogan, M., et al. (2004). Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine, 27, 58–65.CrossRefPubMedGoogle Scholar
  10. 10.
    Chakravarty, E. F., Michaud, K., & Wolfe, F. (2005). Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. Journal of Rheumatology, 32, 2130–2135PubMedGoogle Scholar
  11. 11.
    Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420, 860–867.CrossRefPubMedGoogle Scholar
  12. 12.
    Feldmann, M. (2002). Development of anti-TNF therapy for rheumatoid arthritis. Nature Reviews Immunology, 2, 364–371.CrossRefPubMedGoogle Scholar
  13. 13.
    Ferrajoli, A., Keating, M. J., Manshouri, T., Giles, F. J., Dey, A., Estrov, Z., et al. (2002). The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia. Blood, 100, 1215–1219.PubMedGoogle Scholar
  14. 14.
    Galban, S., Fan, J., Martindale, J. L., Cheadle, C., Hoffman, B., Woods, M. P., et al. (2003). von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays. Molecular & Cellular Biology, 23, 2316–2328.CrossRefGoogle Scholar
  15. 15.
    Glasmacher, A., & von Lilienfeld-Toal, M. (2005). The current status of thalidomide in the management of multiple myeloma. Acta Haematologica, 114, 3–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Greten, F. R., Eckman, L., Greten, T. F., Park, J. M., Li, Z-W., Egan, L. J., et al. (2004). IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285–296.CrossRefPubMedGoogle Scholar
  17. 17.
    Grivennikov, S. I., Tumanov, A. V., Liepinsh, D. J., Kruglov, A. A., Marakusha, B. I., Shakhov, A. N., et al. (2005). Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: Protective and deleterious effects. Immunity, 22, 93–104.PubMedGoogle Scholar
  18. 18.
    Hagemann, T., Robinson, S. C., Schulz, M., Trumper, L., Balkwill, F. R., & Binder, C. (2004). Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent upregulation of matrix metalloproteases. Carcinogenesis, 25, 1543–1549.CrossRefPubMedGoogle Scholar
  19. 19.
    Hagemann, T., Wilson, J., Li, N. F., Leinster, A., Charles, K. A., Kulbe, H., et al. (2005). Macrophages induce invasiveness of epithelial cancer cells via NFκB and JNK. Journal of Immunology, 174(2), 1197–1205.Google Scholar
  20. 20.
    Hehlgans, T., & Pfeffer, K. (2005). The intriguing biology of the tumor necrosis factor/tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology, 115, 1–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Hildebrandt, G. C., Olkiewicz, K. M., Corrion, L. A., Chang, Y., Clouthier, S. G., Liu, C., et al. (2004). Donor-derived TNF-α regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood, 104, 586–593.CrossRefPubMedGoogle Scholar
  22. 22.
    Iocca, H. A., & Isom, H. C. (2003). Tumor necrosis factor-α acts as a complete mitogen for primary rat hepatocytes. American Journal of Pathology, 163, 465–476.PubMedGoogle Scholar
  23. 23.
    Karayiannakis, A. J., Syrigos, K. N., Polychronidis, A., Pitiakoudis, M., Bounovas, A., & Simopoulos, K. (2001). Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Research, 21, 1355–1358.PubMedGoogle Scholar
  24. 24.
    Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., et al. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. New England Journal of Medicine, 345, 1098–1104.CrossRefPubMedGoogle Scholar
  25. 25.
    Kitakata, H., Nemoto-Sasaki, Y., Takahashi, Y., Kondo, T., Mai, M., & Mukaida, N. (2002). Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Research, 62, 6682–6687.PubMedGoogle Scholar
  26. 26.
    Knight, B., Yeoh, G. C. T., Husk, K. L., Ly, T., Abraham, L. J., Yu, C., et al. (2000). Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. Journal of Experimental Medicine, 192, 1809–1818.CrossRefPubMedGoogle Scholar
  27. 27.
    Komori, A., Yatsunami, J., Suganuma, M., Okabe, S., Abe, S., Sakai, A., et al. (1993). Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Research, 53, 1982–1985.PubMedGoogle Scholar
  28. 28.
    Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F., & Kollias, G. (1999). Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. Immunity, 10, 387–398.CrossRefPubMedGoogle Scholar
  29. 29.
    Korner, H., Cretney, E., Wilhelm, P., Kelly, J. M., Rollinghoff, M., Sedgwick, J. D., & et al. (2000). Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. Journal of Experimental Medicine, 191, 89–96.CrossRefPubMedGoogle Scholar
  30. 30.
    Kulbe, H., Hagermann, T., Szlosarek, P. W., Balkwill, F. R., & Wilson, J. L. (2005). The inflammatory cytokine TNF-a upregulates chemokine receptor expression on ovarian cancer cells. Cancer Research, 65, 10355–10362.CrossRefPubMedGoogle Scholar
  31. 31.
    Kuprash, D. V., Tumanov, A. V., Liepinsh, D. J., Koroleva, E. P., Drutskaya, M. S., Kruglov, A. A., et al. (2005). Novel tumor necrosis factor-knockout mice that lack Peyer’s patches. European Journal of Immunology, 35, 1592–1600.CrossRefPubMedGoogle Scholar
  32. 32.
    Kyriakou, C., Thomson, K., D’Sa, S., Flory, A., Hanslip, J., Goldstone, A. H., et al. (2005). Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British Journal of Haematology, 129, 763–770.CrossRefPubMedGoogle Scholar
  33. 33.
    Lejeune, F. J. (2002). Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability. Journal of Clinical Investigation, 110, 433–435.CrossRefPubMedGoogle Scholar
  34. 34.
    Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001). The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell, 104, 487–501.CrossRefPubMedGoogle Scholar
  35. 35.
    Lu, T., & Stark, G. R. (2004). Cytokine overexpression and constitutive NFκB in cancer. Cell Cycle, 3, e69–e72.Google Scholar
  36. 36.
    Luo, J. L., Maeda, S., Hsu, L. C., Yagita, H., & Karin, M. (2004). Inhibition of NFD-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell, 6, 297–305.CrossRefPubMedGoogle Scholar
  37. 37.
    Madhusudan, S., Foster, M., Braybrooke, J., Muthuramalingham, S. R., Wilner, S., Kaur, K. et al. (2004). A phase II study of Etanercept (Enbrel), a tumour necrosis factor-a inhibitor in patients with metastatic breast cancer. Clinical Cancer Research, 10, 6528–6534.CrossRefPubMedGoogle Scholar
  38. 38.
    Madhusudan, S., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., et al. (2005). A phase II study of Ethanercept (ENBREL) a tumour necrosis factor-a inhibitor in recurrent ovarian cancer. Journal of Clinical Oncology, 10, 6528–6534.Google Scholar
  39. 39.
    Maeda, S., Kamata, H., Luo, J. L., Leffert, H., & Karin, M. (2005). IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell, 121, 977–990.CrossRefPubMedGoogle Scholar
  40. 40.
    Malik, S. T. A., Naylor, S., East, N., Oliff, A., & Balkwill, F. R. (1990). Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. European Journal of Cancer, 26, 1031–1034.PubMedCrossRefGoogle Scholar
  41. 41.
    McDermott, M. F. (2001). TNF and TNFR biology in health and disease. Cellular and Molecular Biology, 47, 619–635.PubMedGoogle Scholar
  42. 42.
    Michalaki, V., Syrigos, K., Charles, P., & Waxman, J. (2004). Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. British Journal of Cancer, 91, 1227.CrossRefGoogle Scholar
  43. 43.
    Micheau, O., & Tschopp, J. (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 114, 181–190.CrossRefPubMedGoogle Scholar
  44. 44.
    Moore, R., Owens, D., Stamp, G., East, N., Holdworth, H., Arnott, C., et al. (1999). Tumour necrosis factor-a deficient mice are resistant to skin carcinogenesis. Nature Medicine, 5, 828–831.CrossRefPubMedGoogle Scholar
  45. 45.
    Nabors, L. B., Suswam, E., Huang, Y., Yang, X., Johnson, M. J., & King, P. H. (2003). Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuR. Cancer Research, 63, 4181–4187.PubMedGoogle Scholar
  46. 46.
    Orosz, P., Echtenacher, B., Falk, W., Ruschoff, J., Weber, D., & Mannel, D. N. (1993). Enhancement of experimental metastasis by tumor necrosis factor. Journal of Experimental Medicine, 177, 1391–1398.CrossRefPubMedGoogle Scholar
  47. 47.
    Orosz, P., Kruger, A., Hubbe, M., Ruschoff, J., Von Hoegen, P., & Mannel, D. N. (1995). Promotion of experimental liver metastasis by tumor necrosis factor. International Journal of Cancer, 16, 867–871.Google Scholar
  48. 48.
    Pasparakis, M., Alexopoulou, L., Grell, M., Pfizenmaier, K., Bluethmann, H., & Kollias, G. (1997). Peyer’s patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proceedings of the National Academy of Sciences of the United States of America, 94, 6319–6323.CrossRefPubMedGoogle Scholar
  49. 49.
    Perkins, N. D. (2004). NF-κB: Tumor promoter or suppressor? Trends in Cell Biology, 14, 64–69.CrossRefPubMedGoogle Scholar
  50. 50.
    Pfitzenmaier, J., Vessella, R., Higano, C. S., Noteboom, J. L., Wallace, D. Jr., & Corey, E. (2003). Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer, 97, 1211–1216.CrossRefPubMedGoogle Scholar
  51. 51.
    Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S. et al. (2004). NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 4461–4466.CrossRefGoogle Scholar
  52. 52.
    Raza, A., Candoni, A., Khan, U., Lisak, L., Tahir, S., Silvestri, F. et al. (2004). Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leukemia & Lymphoma, 45, 2099–2104.CrossRefGoogle Scholar
  53. 53.
    Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., et al. (2005). Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet, 366, 1367–1374.CrossRefPubMedGoogle Scholar
  54. 54.
    Schluter, D., Kwok, L.-Y., Lutjen, S., Soltek, S., Hoffmann, S., Korner, H., & Deckert, M. (2003). Both lymphotoxin-α and TNF are crucial for control of Toxoplasma gondii in the central nervous system. Journal of Immunology, 170, 6172–6182.Google Scholar
  55. 55.
    Scott, K. A., Arnott, C. H., Robinson, S. C., Moore, R. J., Thompson, R. G., Marshall, J. F., et al. (2004). TNF-α regulates epithelial expression of MMP-9 and integrin αvβ6 during tumour promotion. A role for TNF-α in keratinocyte migration? Oncogene, 23(41), 6954–6966.CrossRefPubMedGoogle Scholar
  56. 56.
    Seitz, C. S., Lin, Q., Deng, H., & Khavari, P. A. (1998). Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proceedings of the National Academy of Sciences of the United States of America, 95, 2307–2312.CrossRefPubMedGoogle Scholar
  57. 57.
    Sparmann, A., & Bar-Sagi, D. (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell, 6, 447–458.CrossRefPubMedGoogle Scholar
  58. 58.
    Stasi, R., Amadori, S., Newland, A. C., & Provan, D. (2005). Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment of myelodysplastic syndromes. Leukemia & Lymphoma, 46, 509–516.CrossRefGoogle Scholar
  59. 59.
    Stuelten, C. H., DaCosta, B. S., Arany, P. R., Karpova, T. S., Stetler-Stevenson, W. G., & Roberts, A. B. (2005). Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. Journal of Cell Science, 118, 2143–2153.CrossRefPubMedGoogle Scholar
  60. 60.
    Szlosarek, P., & Balkwill, F. (2003). Tumour necrosis factor-α: A potential target in the therapy of solid tumors. Lancet Oncology, 4, 565–573.CrossRefPubMedGoogle Scholar
  61. 61.
    Szlosarek, P. W., Grimshaw, M. J., Kulbe, H., Wilson, J. L., Wilbanks, G. D., Burke, F., et al. (2006). Expression and regulation of tumor necrosis factor-a in normal and malignant ovarian epithelium. Molecular Cancer Therapeutics, 5, 382–390.CrossRefPubMedGoogle Scholar
  62. 62.
    Tisdale, M. J. (2004). Cancer cachexia. Langenbeck’s Archive Surgery, 389, 299–305.PubMedGoogle Scholar
  63. 63.
    Tsan, M.-F. (2005). Toll-like receptors, inflammation and cancer. Seminars in Cancer Biology, 16, 32–37.CrossRefPubMedGoogle Scholar
  64. 64.
    Tsenova, L., Bergtold, A., Freedman, V. H., Young, R. A., & Kaplan, G. (1999). Tumour necrosis factor α is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America, 96, 5657–5662.CrossRefPubMedGoogle Scholar
  65. 65.
    Tsimberidou, A.-M., & Giles, F. J. (2002). TNF-α targeted therapeutic approaches in patients with hematologic malignancies. Expert Review of Anticancer Therapy, 2, 277–286.CrossRefPubMedGoogle Scholar
  66. 66.
    Varfolomeev, E. E., & Ashkenazi, A. (2004). Tumor necrosis factor: An apoptosis JuNKie? Cell, 116, 491–497.CrossRefPubMedGoogle Scholar
  67. 67.
    Wheelhouse, N. M., Chan, Y.-S., Gillies, S. E., Caldwell, H., Ross, J. A., Harrison, D. J., et al. (2003). TNF-α induced DNA damage in primary murine hepatocytes. International Journal of Molecular Medicine, 12, 889–894.PubMedGoogle Scholar
  68. 68.
    Wolfe, F., & Michaud, K. (2004). Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis & Rheumatism, 50, 1740–1751.CrossRefGoogle Scholar
  69. 69.
    Wolfe, F., Michaud, K., Anderson, J., & Urbansky, K. (2004). Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis & Rheumatism, 50, 372–379.CrossRefGoogle Scholar
  70. 70.
    Xanthoulea, S., Pasparakis, M., Kousteini, S., Brakebusch, C., Wallach, D., Bauer, J., et al. (2004). Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. Journal of Experimental Medicine, 200, 367–376.CrossRefPubMedGoogle Scholar
  71. 71.
    Yoshida, N., Ikemoto, S., Narita, K., Sugimura, K., Wada, S., Yasumoto, R., et al. (2002). Interleukin-6, tumour necrosis factor-α and interleukin-1β in patients with renal cell carcinoma. British Journal of Cancer, 86, 1396–1400.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  1. 1.Centre for Translational Oncology, Institute of Cancer and the CR-UK Clinical CentreBarts and The London, Queen Mary’s School of Medicine and DentistryLondonUK

Personalised recommendations